Making Cell And Gene Therapy More Accessible In The Treatment Of Solid Tumors

By Gwyn Bebb, M.D., BM, BCh, Ph.D., Senior Vice President, Global Therapeutic Area Head – Oncology; and Steve Winitsky, Vice President, Technical - Regulatory Strategy

This article delves into the evolving landscape of cell and gene therapies with a focus on expanding access, particularly for solid tumors beyond traditional academic settings. It highlights the established success of CAR-T therapies in hematology and explores the challenges of adapting these treatments to more prevalent solid tumors. The discussion underscores the necessity of broader access for all patients, including those in underserved communities, and explores the feasibility of community-based treatment settings.

Despite regulatory and logistical challenges, recent strides suggest that community sites can effectively manage complex protocols and safety requirements akin to academic centers. Moving forward, enhancing community site capabilities and addressing regulatory considerations will be pivotal in advancing these therapies to benefit a wider patient population.

For further details, read the full article below.